β细胞葡萄糖敏感性可识别3期1型糖尿病免疫干预的临床应答
该研究分析9项3期1型糖尿病II期临床试验中799名参与者的4930个混合餐耐量试验数据点,评估模型推导的β细胞葡萄糖敏感性(βGS)能否补充临床试验策略。结果显示,基线βGS联合年龄、HbA1c和胰岛素剂量可预测干预后HbA1c变化幅度,且正常化βGS比C肽AUC更早指示试验疗效。
要点
- 基线βGS联合年龄、HbA1c、胰岛素剂量可预测干预后HbA1c变化幅度
- 正常化βGS较C肽AUC更早指示临床试验疗效
- βGS变化阈值与干预后血糖管理的临床显著影响相关
核心结论
- 模型推导的β细胞葡萄糖敏感性(βGS)变化阈值与干预后血糖管理的临床显著影响相关。
- 基线βGS联合临床和人口学参数可用于识别更可能对干预应答的个体。
研究设计与样本
- 回顾性分析9项3期1型糖尿病II期临床试验中799名参与者的4930个混合餐耐量试验数据点。
主要发现
- 年龄较大和BMI较高与βGS维持(定义为较基线值丢失<10%)及HbA1c<53 mmol/mol(7.0%)维持相关。
- 基线βGS、年龄、HbA1c和胰岛素剂量共同预测干预后HbA1c变化幅度。
- 比较阳性与阴性试验时,正常化βGS较AUCCp更早指示试验疗效。
关键数值与推荐
- βGS维持定义为较基线值丢失<10%。
- HbA1c维持目标为<53 mmol/mol(7.0%)。
临床怎么用
- 在3期1型糖尿病临床试验中,可考虑将基线βGS联合年龄、HbA1c和胰岛素剂量用于筛选更可能应答的个体。
- 正常化βGS可作为较AUCCp更早的试验疗效指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: At present, no disease-modifying therapies are available for individuals who have been newly diagnosed with type 1 diabetes, despite promising results from decades of clinical trials initiated at stage 3 disease onset. Historically, clinical trials have used changes in the C-peptide AUC (AUCCp) during a mixed meal tolerance test (MMTT) as the primary endpoint; however, this measure does not always correlate with clinical outcomes. METHODS: We analysed 4930 MMTT data points from 799 participants in nine Phase II stage 3 type 1 diabetes trials to determine whether a model-derived physiological measure of in vivo beta cell glucose sensitivity (βGS) could augment clinical trial strategies in type 1 diabetes. RESULTS: Older age and higher BMI were associated with maintenance of βGS (defined as loss <10% of the baseline value) and maintenance of HbA1c <53 mmol/mol (7.0%). Baseline βGS, age, HbA1c and insulin dose together predicted the magnitude of the effect on HbA1c following intervention. When positive and negative trials were compared, normalised βGS served as an earlier indicator of trial efficacy compared with AUCCp. CONCLUSIONS/INTERPRETATION: Our results identified thresholds of change in βGS associated with a clinically significant impact on glycaemic management after intervention and suggest that baseline βGS in association with clinical and demographic parameters may be applied to identify individuals who are more likely to respond to an intervention.
引用
- Evans-Molina C, Gitelman SE, Mari A, et al. Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onset. Diabetologia. 2026. PMID: 41817687. doi:10.1007/s00125-026-06703-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。